Fresh analysis indicates that individuals who come off new weight-loss injections like semaglutide or tirzepatide tend to recover reduced body mass at a significantly accelerated pace than those who end conventional diet and exercise programs.
Published data in a leading medical journal points out that while overweight individuals often shed substantial amounts of their total mass while on the medication, the mass returns at an estimated rate of 0.8 kg per month once they quit.
"People using these drugs must be informed of the danger of rapid rebound weight gain when the medication ends," warns expert Dr. Susan Jebb.
That rate of recovery implies a return to starting mass in about 18 months.
Comparing Therapies
The analysis, which looked at 37 of studies involving over 9,000 of participants, compared the outcomes of the injectable medications with older methods.
The team note that individuals who lose weight through diet and exercise generally have a more gradual weight regain—around 0.1 kg a month—post-intervention.
Understanding the Fast Regain
Nutrition scientists suggest the mode of action of the drugs explains the heightened weight return.
GLP-1 drugs copy a natural hormone called glucagon-like peptide-1, which helps regulate feelings of fullness.
"Artificially providing GLP-1 levels far above than the body's typical production could lead to the system to generate a reduced amount of its own natural hormone, and could diminish sensitivity to its effects," said Dr. Adam Collins, a nutrition expert.
"Stopping of this medication leads to appetite is uncontrolled, making excessive eating much more probable."
A Lifelong Condition?
The NHS advise the injections for individuals with weight-linked medical conditions, alongside prescribed diet and exercise modifications.
A number of clinicians say that, considering the high risk of relapse, the treatment might need to be long-term.
This perspective is echoed by pharmaceutical companies, who state that the results "highlight the long-term character of excess weight," akin to managing conditions like high blood pressure.
User Accounts
Users who have discontinued the medication describe a sudden resurgence of hunger.
"I experienced a switch flipping and I was suddenly starving," described one woman.
This challenge is worsened if patients have not adopted sustainable dietary or behavioural changes during treatment.
Widespread Use
Recent estimates suggest that a significant number of people in the UK have tried weight-loss jabs in the past year, with desire remaining high.
- Adoption is higher among women compared to males.
- The middle-aged demographic shows the highest usage rates.
- Many obtain the medications through private healthcare rather than the NHS.
Ultimately, experts caution that while GLP-1 drugs are powerful tools for shedding pounds, they are not a permanent fix and maintained weight loss relies on combined lifestyle changes.
